Tier 3 — preclinical

Therapeutic potential of senolytic agent quercetin in osteoarthritis: A systematic review and meta-analysis of preclinical studies

Kohei Yamaura, Anna Laura Nelson, Haruki Nishimura, Joan C Rutledge, Sudheer K Ravuri, Chelsea Bahney, Marc J Philippon, Johnny Huard
Ageing research reviews 2023 90:101989

Bibliography

PubMed
PMID 37442369
DOI
10.1016/j.arr.2023.101989
Funding
Indexed funding or support includes National Institutes of Health. The source provides grant details and contributor roles.
Competing interests
Reported disclosure: The authors report the following potential conflicts of interest or sources of funding: Steadman Philippon Research Institute has received grant funding or in-kind donations from Arthrex, DJO, MLB, Ossur, Siemens, Smith & Nephew, and XTRE. JH discloses an unpaid position on the leadership for Orthopaedic Research Society (ORS) and royalties from Cook Myosite. M.J.P. receives support from Smith & Nephew, Linvatec, Bledsoe, DonJoy, Arthrosurface, MIS, Siemens, Arthrex, National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Disease, and National Institute of Aging; and owns stock or stock options in Arthrosurface, MJP Innovations, MIS, and Vail Valley Surgery Center. The other authors have no conflicts of interest to declare. CB discloses unpaid leadership positions for ORS, Tissue Engineering and Regenerative Medicine International Society (TERMIS), and the Orthopaedic Trauma Association (OTA). CB also discloses IP royalties from Iota Biosciences, Inc. for US Patent 041263 and a Review Editor role for Frontiers in Skeletal Physiology.

Study snapshot

DesignSystematic review and meta-analysis of animal osteoarthritis studies
ModelPreclinical evidence synthesis
Sample12 animal studies; 6 in the cartilage-score meta-analysis
InterventionQuercetin across preclinical osteoarthritis models
DurationSearches through March 10, 2023
EndpointsBone or cartilage measures

What the study showed, in plain terms

Published in 2023, this source examined bone and joint health. Design: Systematic review and meta-analysis of animal osteoarthritis studies. Sample/model: 12 animal studies; 6 in the cartilage-score meta-analysis. The exposure or intervention was Quercetin across preclinical osteoarthritis models. Follow-up or treatment period: Searches through March 10, 2023.

Cartilage histology scores favored quercetin in the pooled animal analysis.

High heterogeneity and species or model limitations. Improved animal histology is not proof of human cartilage regeneration or clinical senolysis.

Continue with Quercetin Data Center

For topic-level interpretation, read Is Quercetin a Senolytic? Human Evidence vs Longevity Claims. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Cartilage histology scores favored quercetin in the pooled animal analysis.
  • The recorded outcome domains were Bone or cartilage measures.
  • The result applies to the tested exposure: Quercetin across preclinical osteoarthritis models; Searches through March 10, 2023.

What this study can and cannot tell us

  • High heterogeneity and species or model limitations. Improved animal histology is not proof of human cartilage regeneration or clinical senolysis.
  • Cell concentrations, species, disease models and experimental routes cannot be converted directly into an effective or safe oral human regimen.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology